KRAS in Plasma / ct KRAS

The fully automated IdyllaTM ctKRAS Mutation Test is minimally invasive, fast and easy to perform and can be used as complement to tissue testing to determine the RAS mutation status at diagnosis. IdyllaTM ctKRAS covers 21 KRAS mutations in exons 2,3 and 4 and showed an high concordance to NGS of 96% using plasma samples from 198 mCRC patients enrolled in the prospective multicenter RASANC study.1


One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. With the IdyllaTM system only a minimal amount of sample is needed

  • 1ml plasma collected in Streck tubes (process within 3 days)


26 October 2019

Viewed 358 time

Engine by